Search

Displaying results 1331 - 1340 of 6831 in total
  1. Drug

    Sotagliflozin

    go.drugbank.com/drugs/DB12713
    ApprovedInvestigational

    [L39705] Its potency in inhibiting SGLT2 is similar to that of other SGLT2 inhibitors, such as [canagliflozin] and [dapagliflozin], but its potency in inhibiting SGLT1 is >10-fold higher than its predecessors … [L39734] A similar approval has also been sought in the US, but the FDA has since published a proposal to refuse the approval because the data submitted did not show that it was safe under the proposed

  2. Drug

    Defactinib

    go.drugbank.com/drugs/DB12282
    ApprovedInvestigational

    [L53208,A273943] Defactinib was approved by the US FDA in May 2025 in a co-package alongside [avutometinib] (called Avmapki Fakzynja) for the treatment of recurrent KRAS-mutated low-grade serous ovarian … important for the integrin-mediated activation of several downstream signal transduction pathways, including those involving RAS/MEK/ERK and PI3K/Akt, and its upregulation is a key resistance mechanism to

    Mixtures: Avmapki Fakzynja Co-pack
  3. Drug

    Flurbiprofen

    go.drugbank.com/drugs/DB00712
    ApprovedInvestigational

    Flurbiprofen may also be used topically prior to ocular surgery to prevent or reduce intraoperative miosis. … Flurbiprofen is structurally and pharmacologically related to fenoprofen, ibuprofen, and ketoprofen.

  4. Drug

    Gentamicin

    go.drugbank.com/drugs/DB00798
    ApprovedInvestigationalVet approved

    [A234364] This synergistic activity is not only important for the treatment of complex infections, but can also contribute to dose optimization and reduced adverse effects. … [A234339,A234354] Gentamicin is effective against both gram-positive and gram-negative organisms but is particularly useful for the treatment of severe gram-negative infections including those caused by

    Mixtures: FITODERM TC, Gentamicin Sulfate In Nacl O.9% Inj
  5. Drug

    Synthetic Conjugated Estrogens, A

    go.drugbank.com/drugs/DB09317
    Approved

    However, once a woman stops ovulating there is a sharp decline in the production of progesterone and estradiol by the ovaries and a consequent fluctuation in LH and FSH due to a lack of feedback control … These symptoms are able to be reduced by replacing many of the hormones lost during and following menopause with synthetic or naturally occurring forms, in a therapy known as Hormone Replacement Therapy

  6. Drug

    Esmolol

    go.drugbank.com/drugs/DB00187
    ApprovedInvestigationalWithdrawn

    It works by blocking beta-adrenergic receptors in the heart, which leads to decreased force and rate of heart contractions. … It has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic or membrane stabilizing activities at recommended therapeutic doses.

  7. Drug

    Sufentanil

    go.drugbank.com/drugs/DB00708
    ApprovedInvestigational

    This route of administration is intended to be a simple, effective, non-invasive analgesic option to enable healthcare professionals to rapidly manage acute pain without difficult intravenous or epidural … It is administered by the intravenous, epidural and sublingual routes.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  8. Drug

    Tiratricol

    go.drugbank.com/drugs/DB03604
    ApprovedInvestigational

    by chronic tissue thyrotoxicosis and abnormal neuronal development due to the impaired thyroid hormone uptake in the brain. … Tiratricol is an analogue and active metabolite of the thyroid hormone triiodothyronine (T3).

    Categories: Agents used to treat hypothyroidism
  9. Drug

    Sulopenem etzadroxil

    go.drugbank.com/drugs/DB16335
    ApprovedInvestigational

    [L51858] It is administered in combination with [probenecid] in order to increase antibiotic exposure.[L51768] … [L51768] Sulopenem etzadroxil was approved by the FDA in October 2024 for the treatment of uncomplicated urinary tract infections.

  10. Drug

    Moxetumomab pasudotox

    go.drugbank.com/drugs/DB12688
    ApprovedInvestigational

    This antibody was used to generate a recombinant immunotoxin in which a stabilized Fv segment by a disulfide bond is fused to the _Pseudomonas_ exotoxin A (PE38) which does not have the cell-binding portion … [A38864] MxP appears as an improved form of BL22 by the mutation of the Fv region and the antibody phage-displayed. As well the residues SSY in the heavy chain are mutated to THW.